FAO:XXXXXX (XXXX), XXXXXX (XXXX)

Alopecia UK

Sent by e-mail only: XXXXXXXXXX and XXXXXXXXXX

28 June 2023

Dear XXXXXX and ,XXXXXX

**Re: Final Appraisal Document — Baricitinib for treating severe alopecia areata [ID3979]**

I refer to your appeal of 25 May 2023 and my initial scrutiny letter of 9 June 2023. I note that you have confirmed that you have chosen not to submit a response to my initial scrutiny views. This is therefore my final decision on initial scrutiny.

The valid appeal points that will be considered by the appeal panel are:

* Appeal point 2.2 [your second bullet point under appeal point 2 in your appeal letter]: The committee's reliance on the HRQoL tool rather than a more disease specific HRQoL tool was unreasonable;
* Appeal point 2.3 [your third bullet point under appeal point 2 in your appeal letter]: Not considering those people for whom severe alopecia areata can have a large negative impact on quality of life as a subgroup was unreasonable;
* Appeal point 2.5 [your fifth bullet point under appeal point 2 in your appeal letter]: Having acknowledged unmet need (para 3.2 of the FAD), it was unreasonable for the committee not to recommend baricitinib;
* Appeal point 2.7 [your seventh bullet point under appeal point 2 in your appeal letter]: Having acknowledged uncaptured treatment benefits and concluded that baricitinib is innovative (para 3.18 of the FAD), it was unreasonable for the committee not to consider baricitinib with managed access.

Conclusion

The above sets out above my final decision on all of your appeal points.

NICE will be in contact with you regarding the administration of the appeal, which will be held orally.

Yours sincerely,

XXXXXXXXXX

Dr Mark Chakravarty

Lead Non-Executive Director for Appeals & Vice Chairman

National Institute for Health and Care Excellence